Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Journal Articles

Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia : A Graall Study from the Descar-T Registry

Blood (2023) 142 (Supplement 1): 3498.

https://doi.org/10.1182/blood-2023-180575

Published: 2023

Journal Articles

Checkpoint Inhibitors and Allo-SCT in Hodgkin Lymphoma: A Matter of Time - a Study By the SFGM-TC

Blood (2023) 142 (Supplement 1): 4926.

https://doi.org/10.1182/blood-2023-184836

Published: 2023

Journal Articles

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Blood (2023) 142 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2023-174883

Published: 2023

Journal Articles

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Blood (2022) 140 (24): 2584–2593.

https://doi.org/10.1182/blood.2022016945

Published: 2022

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Blood (2022) 140 (Supplement 1): 276–278.

https://doi.org/10.1182/blood-2022-163340

Published: 2022

Journal Articles

Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Blood (2022) 140 (Supplement 1): 1859–1861.

https://doi.org/10.1182/blood-2022-167840

Published: 2022

Journal Articles

Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry

Hedi Bensaber, Emmanuel Bachy, David Beauvais, Remy Dulery, Thomas Gastinne, Bruno Villemagne, Louise Roulin, Etienne Paubelle, Cristina Castilla-Llorente, Thomas Longval, Elodie Gat, Amandine Fayard, Jacques-Olivier Bay, Steven Le Gouill, Roch Houot, Romain Guieze

Blood (2022) 140 (Supplement 1): 3803–3804.

https://doi.org/10.1182/blood-2022-158807

Published: 2022

Journal Articles

A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry

Blood (2021) 138 (Supplement 1): 92.

https://doi.org/10.1182/blood-2021-150721

Published: 2021

Journal Articles

Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry

Blood (2021) 138 (Supplement 1): 885.

https://doi.org/10.1182/blood-2021-150994

Published: 2021

Journal Articles

Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients

Sara Villar, Sylvie Chevret, Xavier Poire, Amandine Charbonnier, Patrice Chevallier, Jean-Henri Bourhis, Edouard Forcade, Sylvain Chantepie, David Beauvais, Nicole Raus, Jacques-Olivier Bay, Michael Loschi, Raynier Devillier, Remy Duléry, Patrice Ceballos, Marie Thérèse Rubio, Yves Beguin, Stephanie Nguyen, Marie Robin

Blood (2021) 138 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2021-146380

Published: 2021

Journal Articles

Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group

Blood (2021) 138 (Supplement 1): 743.

https://doi.org/10.1182/blood-2021-148626

Published: 2021

Journal Articles

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Eileen Mary Boyle, MD MSc, Marie-Odile Petillon, MD, Charles Herbaux, MD, Johanna Mimouni, Xavier Leleu, Lionel Karlin, MD, Chantal Doyen, MD, Marc Wetterwald, MD PhD, Muriel Roussel, MD, Cyrille Hulin, Bruno Royer, MD, Margaret Macro, Philippe Moreau, Karel Fostier, MD, Mamoun Dib, Sabine Brechignac, MD, Caroline Bureau, Gerald Marit, MD, Adrian Tempescul, MD, Marie Lorraine Chretien, Charles Zarnitsky, Cecile Fohrer, MD, Aurore Perrot, MD, Lotfi Benboubker, MD PhD, Laurent Voillat, Jean Valere Malfuson, Clara Mariette, Mourad Tiab, Sophie Rigaudeau, Arnaud Jaccard, MD PhD, Anne-Marie Stoppa, Laure Vincent, Jean Claude Eisenmann, MD, Laurent Frenzel, Bertrand Arnulf, MD, Mohamad Mohty, MD PhD, Philippe Rodon, MD, Brigitte Kolb, Olivier Decaux, MD PhD, Pascal Godmer, David Beauvais, Benjamin Carpentier, Sarah Bonnet, MD, Thomas Longval, Mathieu Dewevre, Herve Avet-Loiseau, MD PhD, Michel Attal, Susanna Schraen, PharmD, Thierry Facon

Blood (2016) 128 (22): 2138.

https://doi.org/10.1182/blood.V128.22.2138.2138

Published: 2016

Journal Articles

Monitoring of Wilms’ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation

Remy Dulery, MD, Olivier Nibourel, PhD, Vincent Elsermans, David Beauvais, MD, Arthur Simonnet, MD, Jordan Gauthier, MD, Valérie Coiteux, MD, Leonardo Magro, MD, Bruno Quesnel, MD, Claude Preudhomme, Ibrahim Yakoub-Agha, MD PhD

Blood (2014) 124 (21): 1265.

https://doi.org/10.1182/blood.V124.21.1265.1265

Published: 2014

Journal Articles

Plasma Citrulline Level As a Biochemical Marker to Predict and Diagnose Graft-Versus-Host Disease

Benjamin Carpentier, MD, Remy Dulery, MD, David Seguy, MD, David Beauvais, MD, Arthur Simonnet, MD, Jordan Gauthier, MD, Valérie Coiteux, MD, Leonardo Magro, MD, Ibrahim Yakoubagha, MD

Blood (2014) 124 (21): 3931.

https://doi.org/10.1182/blood.V124.21.3931.3931

Published: 2014

Journal Articles

Prognostic Of IgD Myeloma In The Era Of Novel Agents

Blood (2013) 122 (21): 1880.

https://doi.org/10.1182/blood.V122.21.1880.1880

Published: 2013

Journal Articles

Impact Of Initial FGD-PET CT and Serum Free Light Chain On Transformation Of Solitary Plasmacytoma To MM

Guillemette Fouquet, MD, Stéphanie Guidez, MD, Charles Herbaux, MD, Zoé Van de Wyngaert, MD, Sarah Bonnet, MD, David Beauvais, MD, Helene Demarquette, MD, Bénédicte Hivert, MD, Mathieu Wemeau, MD, Louis Terriou, MD, Valérie Coiteux, Margaret Macro, MD, Olivier Decaux, MD, Thierry Facon, MD, Damien Huglo, MD, PhD, Xavier Leleu, MD, PhD

Blood (2013) 122 (21): 1888.

https://doi.org/10.1182/blood.V122.21.1888.1888

Published: 2013

Journal Articles

Safety Profile Of Bortezomib Impacts Survival Of Cardiac AL Amyloidosis

Zoé Van de Wyngaert, MD, Greg Vanoutryve, Charles Herbaux, MD, Guillemette Fouquet, MD, Helene Demarquette, MD, Sarah Bonnet, MD, David Beauvais, MD, Stéphanie Guidez, MD, Nicolas Lamblin, MD, Eric Hachulla, MD, PhD, David Launay, Louis Terriou, MD, Bénédicte Hivert, MD, Mathieu Wemeau, MD, Xavier Leleu, MD, PhD

Blood (2013) 122 (21): 5316.

https://doi.org/10.1182/blood.V122.21.5316.5316

Published: 2013

NARROW

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia : A Graall Study from the Descar-T Registry

Checkpoint Inhibitors and Allo-SCT in Hodgkin Lymphoma: A Matter of Time - a Study By the SFGM-TC

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry

A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry

Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry

Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients

Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Monitoring of Wilms’ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation

Plasma Citrulline Level As a Biochemical Marker to Predict and Diagnose Graft-Versus-Host Disease

Prognostic Of IgD Myeloma In The Era Of Novel Agents

Impact Of Initial FGD-PET CT and Serum Free Light Chain On Transformation Of Solitary Plasmacytoma To MM

Safety Profile Of Bortezomib Impacts Survival Of Cardiac AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only